California Cancer Reporting System Standards Volume I: Abstracting and Coding Procedures for Hospitals
PRIOR 2010
Although borderline ovarian tumors changed behavior in ICD-O-3 from /3 (malignant) to /1 (borderline), the CCR will continue to require reporting them. They are to be coded with a behavior code of /1.
As listed in Appendix 6 of the ICD-O-3 Code Manual, reportable borderline ovarian tumors include the following terms and morphology codes:
Serous cystadenoma, borderline malignancy |
8442/1 |
Serous tumor, NOS, of low malignant potential |
8442/1 |
Papillary cystadenoma, borderline malignancy |
8451/1 |
Serous papillary cystic tumor of borderline malignancy |
8462/1 |
Papillary serous cystadenoma, borderline malignancy |
8462/1 |
Papillary serous tumor of low malignant potential |
8462/1 |
Atypical proliferative papillary serous tumor |
8462/1 |
Mucinous cystic tumor of borderline malignancy |
8472/1 |
Mucinous cystadenoma, borderline malignancy |
8472/1 |
Pseudomucinous cystadenoma, borderline malignancy |
8472/1 |
Mucinous tumor, NOS, of low malignant potential |
8472/1 |
Papillary mucinous cystadenoma, borderline malignancy |
8473/1 |
Papillary pseudomucinous cystadenoma, borderline malignancy |
8473/1 |
Papillary mucinous tumor of low malignant potential |
8473/1 |
January 1, 2008 and Forward
Beginning with the implementation of Collaborative Staging, Version 01.04.00, and for borderline ovarian cases diagnosed on or after January 1, 2008, code CS Extension to 99.
January 1, 2004 and Forward
Apply the Collaborative Staging ovary scheme for cases diagnosed on or after January 1, 2004. Do not use Collaborative Staging Extension code 00 (in situ) for borderline ovarian tumors. Follow-up is required for these cases.
Prior to January 1, 2004
For cases diagnosed prior to January 1, 2004, these cases are to be staged according to the ovary scheme in the EOD Manual.